A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms FOURIER; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 01 Dec 2017 According to an Amgen media release, the U.S. Food and Drug Administration (FDA) approved Repatha (evolocumab), to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.
    • 15 Nov 2017 Results of analysis identifying patients who have greatest potential for benefit from evolocumab by risk stratification with the TIMI risk score for secondary prevention presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results assessing effect of Evolocumab on spontaneous myocardial infarction regardless of size and type (NSTEMI or STEMI) presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top